Literature DB >> 18321156

Emerging drugs for rheumatoid arthritis.

Paraskevi V Voulgari1.   

Abstract

BACKGROUND: Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic, autoimmune disease characterized by symmetric arthritis of diarthrodial joints leading to progressive erosion of cartilage and bone. The individual and social impacts of RA are of great importance.
OBJECTIVE: To investigate the development of new therapies for RA treatment.
METHODS: Various databases have been searched for new drugs in clinical trials (Phase I - III) and experimental future therapeutic agents for RA. RESULTS/
CONCLUSION: The current management of the disease includes the use of disease modifying anti-rheumatic drugs and the biologic therapies. Progress in our understanding of RA pathophysiology led to the identification of new therapeutic targets. These include pro-inflammatory cytokines, T and B cells, adhesion molecules, chemokines and intra- and extracellular signaling pathways. Therapeutic modulation of the above targets can provide new treatment strategies. This article reviews a few of the new treatment strategies currently being evaluated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321156     DOI: 10.1517/14728214.13.1.175

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN: 1472-8214            Impact factor:   4.191


  3 in total

Review 1.  New complexities in helper T cell fate determination and the implications for autoimmune diseases.

Authors:  Hiroaki Takatori; Yuka Kanno; Zhi Chen; John J O'Shea
Journal:  Mod Rheumatol       Date:  2008-08-05       Impact factor: 3.023

Review 2.  Advances in rheumatology: new targeted therapeutics.

Authors:  Paul P Tak; Joachim R Kalden
Journal:  Arthritis Res Ther       Date:  2011-05-25       Impact factor: 5.156

3.  The exploration of network motifs as potential drug targets from post-translational regulatory networks.

Authors:  Xiao-Dong Zhang; Jiangning Song; Peer Bork; Xing-Ming Zhao
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.